Aquestive Therapeutics (AQST) Non-Current Debt (2017 - 2026)
Aquestive Therapeutics (AQST) posted quarterly Non-Current Debt of $45.0 million for Q1 2026, up 33.35% year-over-year from $33.7 million in Q1 2025, and up 63.52% quarter-over-quarter from $27.5 million in Q4 2025.
Aquestive Therapeutics (AQST) Non-Current Debt (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' Non-Current Debt history runs 10 years deep, the most recent figure standing at $45.0 million for Q1 2026.
- In Q1 2026, Non-Current Debt rose 33.35% year-over-year to $45.0 million; the TTM figure through Mar 2026 stood at $45.0 million (up 33.35% YoY), while the FY2025 annual figure was $27.5 million, down 15.33% from the prior year.
- Non-Current Debt for Q1 2026 stood at $45.0 million, up from $27.5 million in the prior quarter.
- The five-year high for Non-Current Debt was $47.7 million in Q1 2022, with the low at $17.5 million in Q2 2024.
- The 5-year median for Non-Current Debt is $33.7 million (2025), against an average of $35.4 million.
- The sharpest annual moves came in 2024 and 2025: Non-Current Debt sank 55.16% in 2024, then soared 82.2% in 2025.
- Aquestive Therapeutics' Non-Current Debt stood at $33.4 million in 2022, then slipped by 17.76% to $27.5 million in 2023, then grew by 18.15% to $32.5 million in 2024, then retreated by 15.33% to $27.5 million in 2025, then soared by 63.52% to $45.0 million in 2026.
- Business Quant data shows AQST's Non-Current Debt at $45.0 million in Q1 2026, $27.5 million in Q4 2025, and $29.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 130.00 Mn |
| 10 | Aquestive Therapeutics | 560.60 Mn | 560.60 Mn | 9.80 Mn | 55.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 55.00 Mn |
| Mar 31, 2026 | 45.00 Mn |
| Dec 31, 2025 | 27.52 Mn |
| Sep 30, 2025 | 29.94 Mn |
| Jun 30, 2025 | 31.84 Mn |
| Mar 31, 2025 | 33.75 Mn |
| Dec 31, 2024 | 32.50 Mn |
| Sep 30, 2024 | 45.00 Mn |
| Jun 30, 2024 | 17.48 Mn |
| Mar 31, 2024 | 45.00 Mn |
| Dec 31, 2023 | 27.51 Mn |
| Sep 30, 2023 | 38.98 Mn |
| Jun 30, 2023 | 38.98 Mn |
| Mar 31, 2023 | 25.20 Mn |
| Dec 31, 2022 | 33.45 Mn |
| Sep 30, 2022 | 38.68 Mn |
| Jun 30, 2022 | 43.82 Mn |
| Mar 31, 2022 | 47.68 Mn |
| Dec 31, 2021 | 51.55 Mn |
| Sep 30, 2021 | 32.67 Mn |